glp 1 agonist eli lilly The GLP-1 market is projected to exceed 100B USD by 2030 Eli Lilly's retatrutide shows promising
Description
Friedman DI, et al
Nevertheless, current evidence supports GLP-1 RAs and multi-agonist formulations as highly promising pharmacotherapies that address the complex, multifactorial pathophysiology of MASLD while simultaneously improving cardiometabolic comorbidities, positioning them as cornerstone treatments in the evolving therapeutic landscape for this prevalent and burdensome disease
10.3810/pgm.2010.05.2138 62 FriedrichC.PortA.RingA.Graefe-ModyU.GiessmannT.IovinoM.et al (2011)
Cost of Popular Weight Loss Drugs Goes Down for People Without Insurance
Renee Rayburg, PSGs vice president of specialty clinical consulting, told Fierce Healthcare in an email that the drugs have not been on the market long enough to provide any historical data
authors reported the odds ratio
